Kantonsspital St.Gallen

Andrej Besse

Medizinische Onkologie und Hämatologie · Dept. I

Kontakt

Andrej Besse
Switzerland

T +41 762952577

andrej.besse@kssg.ch

Bereiche

Medizinische Onkologie und Hämatologie

Publikationen (16)

Besse L, Kraus M, Besse A, Driessen C, Tarantino I. The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma. Sci Rep 2023; 13:4411.

Kliebhan J, Besse A, Kampa-Schittenhelm K, Schittenhelm M, Driessen C. Mutant driving the Warburg Effect in Mantle Cell lymphoma. Clin Case Rep 2022; 10:e6296.

Schwestermann J, Besse A, Driessen C, Besse L. Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors. Front Oncol 2022; 12:899272.

Bolomsky A, Caers J, Hübl W, Schreder M, Zojer N, Driessen C, Tang J, Besse L, Heckman C, Kubicek S, Hannich J, Miettinen J, Malyutina A, Besse A, Huber J, Fellinger S, Breid H, Parsons A, Klavins K, Ludwig H. Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma. Blood Adv 2021; 5:4125-4139.

Besse L, Besse A, Kraus M, Maurits E, Overkleeft H, Bornhauser B, Bourquin J, Driessen C. High Immunoproteasome Activity and sXBP1 in Pediatric Precursor B-ALL Predicts Sensitivity towards Proteasome Inhibitors. Cells 2021; 10

Ring S, Spiegl M, Besse A, Bonilla W, Stemeseder F, Schmidt S, Orlinger K, Krebs P, Ludewig B, Wenger R, Hartmann F, Cupovic J, Onder L, Lütge M, Pérez Shibayama C, Gil Cruz C, Scandella E, De Martin A, Mörbe U, Flatz L. Viral vector-mediated reprogramming of the fibroblastic tumor stroma sustains curative melanoma treatment. Nat Commun 2021; 12:4734.

Besse L, Bolomsky A, Ludwig H, Hannich J, Loguinov A, Everts B, Berkers C, Pilon M, Farhan H, Vulpe C, Overkleeft H, Huber J, Ståhlman M, Borén J, Besse A, Stolze S, Sobh A, Zaal E, van der Ham A, Ruiz M, Phuyal S, Büchler L, Sathianathan M, Florea B, Driessen C. Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma. Cancer Res 2021; 81:4581-4593.

Byrgazov K, Besse A, Kraus M, Slipicevic A, Lehmann F, Driessen C, Besse L. Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells. Hemasphere 2021; 5:e602.

Byrgazov K, Kraus M, Besse A, Slipicevic A, Lehmann F, Driessen C, Besse L. Up-regulation of multidrug resistance protein MDR1/ABCB1 in carfilzomib-resistant multiple myeloma differentially affects efficacy of anti-myeloma drugs. Leuk Res 2020; 101:106499.

Driessen C, Pabst T, Hitz F, Hawle H, Rondeau S, Berset C, Besse A, Besse L, Ribi K, Samaras P, Mey U, Rüfer A, Mach N, Betticher D, Cantoni N, Novak U, Müller R, Zander T. Promising activity of nelfinavir-bortezomib-dexamethasone (NeVd) in proteasome inhibitor-refractory multiple myeloma. Blood 2018

Barrio S, Martinez-Lopez J, Rosenwald A, Beckmann R, Bargou R, Braggio E, Stewart A, Raab M, Einsele H, Driessen C, Chatterjee M, Leich E, Stühmer T, Da-Viá M, Barrio-Garcia C, Lehners N, Besse A, Cuenca I, Garitano-Trojaola A, Fink S, Kortüm K. Spectrum and functional validation of PSMB5 mutations in multiple myeloma. Leukemia 2018

Krupkova O, Cambria E, Besse L, Besse A, Bowles R, Wuertz-Kozak K. The potential of CRISPR/Cas9 genome editing for the study and treatment of intervertebral disc pathologies. JOR Spine 2018; 1:e1003.

Abt D, Driessen C, Engeler D, Schmid H, Slaby O, Vodinska M, Silzle T, Bader J, Kraus M, Sedlarikova L, Besse A, Besse L. Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir. BJU Int 2017

Besse L, Kraus M, Besse A, Bader J, Silzle T, Mehrling T, Driessen C. The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways. Blood Cancer J 2017; 7:e589.

Besse A, Besse L, Overkleeft H, Bader J, Kraus M, Morgan G, Weinhold N, Rasche L, Stolze S, Driessen C. Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma. Leukemia 2017; 32:391-401.

Xin B, Groll M, Driessen C, van der Stelt M, Kisselev A, van der Marel G, Filippov D, Florea B, Besse A, Huber E, de Bruin G, Overkleeft H. Structure-Based Design of β5c Selective Inhibitors of Human Constitutive Proteasomes. J Med Chem 2016; 59:7177-87.

Projekte (8)

Genetic contributors of multiple myeloma cells involved in their homing and escape from T-cell recognition

Grundlagenforschung - 01.07.2022 - 30.06.2023

Automatisch geschlossen

ALK-Inhibitoren als potentielle Therapie bei Proteasom-Inhibitor-resistentem Multiplen Myelom

Grundlagenforschung - 01.10.2021 - 30.09.2023

Automatisch geschlossen

Immunoproteasome activity as a predictive marker and therapeutic target in hematological malignancies

Grundlagenforschung - 01.07.2021 - 31.12.2021

Automatisch geschlossen

Towards identification of novel therapeutic targets: Assessment of proteasome-related alterations in MM patients' datasets

Grundlagenforschung - 01.01.2021 - 31.12.2021

Automatisch geschlossen

The molecular landscape of proteasome inhibitor resistance of multiple myeloma in vivo

Grundlagenforschung - 01.07.2020 - 31.12.2023

Automatisch geschlossen

The „seed and soil"-based pathogenesis of proteasome inhibitor resistance in multiple myeloma

Grundlagenforschung - 01.01.2019 - 31.12.2019

Automatisch geschlossen

Identifying and targeting the "Achilles' heel" in proteasome inhibitor-resistant multiple myeloma

Grundlagenforschung - 01.10.2018 - 31.12.2021

Automatisch geschlossen

HIV-Proteaseinhibitoren als Basis für Krebstherapie: Verständnis des Mechanismus, Identifikation der Targets, Entwicklung wirksamerer Substanzen

Grundlagenforschung - 01.11.2016 - 31.10.2018

Automatisch geschlossen